Literature DB >> 4025261

Clostridium difficile in patients with cystic fibrosis.

C J Welkon, S S Long, C M Thompson, P H Gilligan.   

Abstract

One hundred seven patients with cystic fibrosis (CF) and 54 other patients with risk factors for Clostridium difficile-associated disease were entered into a bacteriologic study to compare the rate of recovery of C difficile and cytotoxin in feces with occurrence of diarrhea and to investigate potentially protective or permissive relationships of fecal flora. Toxigenic C difficile was recovered from 22% of CF patients and 11% of patients with other diagnoses. Unlike the latter group, the majority (12/15) of CF patients who had cytotoxin recovered had formed stools and no history of diarrhea. Explanations for the lack of symptoms are speculative. Stool flora of CF patients was significantly more likely to include several bacteria with known inhibitory effects on C difficile. Recovery of C difficile and cytotoxin, however, was not associated with the decrease in rate of recovery or the mean bacterial count of any bacterium of fecal flora.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4025261     DOI: 10.1001/archpedi.1985.02140100067032

Source DB:  PubMed          Journal:  Am J Dis Child        ISSN: 0002-922X


  16 in total

1.  Clostridium difficile colitis in children with cystic fibrosis.

Authors:  Sunny Zaheed Hussain; Cathy Chu; David P Greenberg; David Orenstein; Seema Khan
Journal:  Dig Dis Sci       Date:  2004-01       Impact factor: 3.199

2.  Binary toxin and its clinical importance in Clostridium difficile infection, Belgium.

Authors:  T Pilate; J Verhaegen; M Van Ranst; V Saegeman
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-07-08       Impact factor: 3.267

3.  Asymptomatic carriage of Clostridium difficile in patients with cystic fibrosis.

Authors:  S L Peach; S P Borriello; H Gaya; F E Barclay; A R Welch
Journal:  J Clin Pathol       Date:  1986-09       Impact factor: 3.411

4.  Profiling Humoral Immune Responses to Clostridium difficile-Specific Antigens by Protein Microarray Analysis.

Authors:  Ola H Negm; Mohamed R Hamed; Elizabeth M Dilnot; Clifford C Shone; Izabela Marszalowska; Mark Lynch; Christine E Loscher; Laura J Edwards; Patrick J Tighe; Mark H Wilcox; Tanya M Monaghan
Journal:  Clin Vaccine Immunol       Date:  2015-07-15

5.  A new role for heat shock factor 27 in the pathophysiology of Clostridium difficile toxin B.

Authors:  Murali K Yanda; William B Guggino; Liudmila Cebotaru
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2019-11-11       Impact factor: 4.052

Review 6.  Clostridium difficile: its disease and toxins.

Authors:  D M Lyerly; H C Krivan; T D Wilkins
Journal:  Clin Microbiol Rev       Date:  1988-01       Impact factor: 26.132

7.  New role for human α-defensin 5 in the fight against hypervirulent Clostridium difficile strains.

Authors:  Lucinda Furci; Rossella Baldan; Valentina Bianchini; Alberto Trovato; Cristina Ossi; Paola Cichero; Daniela M Cirillo
Journal:  Infect Immun       Date:  2014-12-29       Impact factor: 3.441

Review 8.  Crohn's disease and cystic fibrosis.

Authors:  J D Lloyd-Still
Journal:  Dig Dis Sci       Date:  1994-04       Impact factor: 3.199

9.  Laboratory diagnosis of Clostridium difficile-associated gastrointestinal disease: comparison of a monoclonal antibody enzyme immunoassay for toxins A and B with a monoclonal antibody enzyme immunoassay for toxin A only and two cytotoxicity assays.

Authors:  G V Doern; R T Coughlin; L Wu
Journal:  J Clin Microbiol       Date:  1992-08       Impact factor: 5.948

10.  Antibiotic-associated colitis and cystic fibrosis.

Authors:  C S Pokorny; P T Bye; C MacLeod; W S Selby
Journal:  Dig Dis Sci       Date:  1992-09       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.